Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2025-12-25 @ 4:30 AM
NCT ID:
NCT01503918
Eligibility Criteria:
Inclusion Criteria:
* Total hospital stay of less than 7 days
* CMV seropositive
* Critical care stay of \>24 hours
* Mechanically ventilated, anticipated to continue for \> 48 hours
Exclusion Criteria:
* Known Pregnancy or breast feeding
* Expected to survive less than 48 hours
* Confirmed immunosuppression
* Known or suspected Human Immunodeficiency Virus infection
* Known or suspected underlying immunodeficiency (organ transplantation including stem cell transplantation on immunosuppression, congenital immunodeficiency, in receipt of immunosuppressive medication e.g. azathioprine, methotrexate, tacrolimus, cyclosporine, sirolimus, cyclophosphamide within 30 days)
* Corticosteroids: Prednisolone chronic administration may be used up to a dose of 10mg/day on average over the preceding 30 days, stress dose hydrocortisone (up to 400mg/day) may be used, topical steroids may be used, short duration of higher dose steroids for exacerbations of chronic obstructive pulmonary disease (COPD) up to 1mg/kg prednisolone or equivalent are permitted for up to 14 days
* Receipt of chemotherapeutic agent within the last 6 months
* Use of systemic antiviral medication other than oseltamivir within the last 7 days.
* Intubated and mechanically ventilated secondary to brain injury alone.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01503918
Study Brief:
Protocol Section:
NCT01503918